{"id":"https://openalex.org/W4407698276","doi":"https://doi.org/10.70534/armw8170","title":"Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia","display_name":"Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia","publication_year":2024,"publication_date":"2024-01-01","ids":{"openalex":"https://openalex.org/W4407698276","doi":"https://doi.org/10.70534/armw8170"},"language":"en","primary_location":{"id":"doi:10.70534/armw8170","doi":"https://doi.org/10.70534/armw8170","is_oa":true,"landing_page_url":"https://doi.org/10.70534/armw8170","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.70534/armw8170","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054537221","display_name":"Brandon O. Klee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandon Klee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045792195","display_name":"Keito Hoshitsuki","orcid":"https://orcid.org/0000-0002-6723-0711","observed_orcids":["https://orcid.org/0000-0002-6723-0711"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keito Hoshitsuki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039997334","display_name":"John Carl Panetta","orcid":"https://orcid.org/0000-0003-1308-7208","observed_orcids":["https://orcid.org/0000-0003-1308-7208"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carl Panetta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035759509","display_name":"Wenjian Yang","orcid":"https://orcid.org/0000-0002-7305-5649","observed_orcids":["https://orcid.org/0000-0002-7305-5649"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenjian Yang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005274385","display_name":"Seth E. Karol","orcid":"https://orcid.org/0000-0001-8113-8180","observed_orcids":["https://orcid.org/0000-0001-8113-8180"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Seth Karol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044548428","display_name":"Yinmei Zhou","orcid":"https://orcid.org/0009-0007-4458-5556","observed_orcids":["https://orcid.org/0009-0007-4458-5556"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yinmei Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085620590","display_name":"Kristine R. Crews","orcid":"https://orcid.org/0000-0002-7558-558X","observed_orcids":["https://orcid.org/0000-0002-7558-558X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristine Crews","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100349399","display_name":"Cheng Cheng","orcid":"https://orcid.org/0000-0001-9226-1547","observed_orcids":["https://orcid.org/0000-0001-9226-1547"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cheng Cheng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015786975","display_name":"William E. Evans","orcid":"https://orcid.org/0000-0002-0357-7169","observed_orcids":["https://orcid.org/0000-0002-0357-7169"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Evans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018363328","display_name":"Ching\u2010Hon Pui","orcid":"https://orcid.org/0000-0003-0303-5658","observed_orcids":["https://orcid.org/0000-0003-0303-5658"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ching-Hon Pui","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075936752","display_name":"Hiroto Inaba","orcid":"https://orcid.org/0000-0003-0605-7342","observed_orcids":["https://orcid.org/0000-0003-0605-7342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hiroto Inaba","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061426227","display_name":"Jun Yang","orcid":"https://orcid.org/0000-0002-4233-3220","observed_orcids":["https://orcid.org/0000-0002-4233-3220"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Yang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5057584809","display_name":"Hope D. Swanson","orcid":"https://orcid.org/0009-0000-2490-9655","observed_orcids":["https://orcid.org/0009-0000-2490-9655"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hope Swanson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.50700137,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.8529999852180481},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.8740000128746033},{"id":"https://openalex.org/keywords/genetic-variation","display_name":"genetic variation","score":0.9169999957084656},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.7940000295639038},{"id":"https://openalex.org/keywords/high-dose-chemotherapy","display_name":"high-dose chemotherapy","score":0.8240000009536743},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/pediatric-leukemia","display_name":"pediatric leukemia","score":0.6399999856948853}],"concepts":[{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.8036863803863525},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.746436595916748},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6197439432144165},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5640825033187866},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.47649139165878296},{"id":"https://openalex.org/C2781107101","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Acute lymphocytic leukemia","level":4,"score":0.4173774719238281},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.395248144865036},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2989794611930847},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24506089091300964}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.70534/armw8170","doi":"https://doi.org/10.70534/armw8170","is_oa":true,"landing_page_url":"https://doi.org/10.70534/armw8170","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.70534/armw8170","doi":"https://doi.org/10.70534/armw8170","is_oa":true,"landing_page_url":"https://doi.org/10.70534/armw8170","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4366126670","https://openalex.org/W2079343323","https://openalex.org/W4312417359","https://openalex.org/W7005181403","https://openalex.org/W2296018923","https://openalex.org/W7100957893","https://openalex.org/W2078208523","https://openalex.org/W3184473673","https://openalex.org/W2351357739","https://openalex.org/W2203355473"],"abstract_inverted_index":{"Objectives:":[0],"High-dose":[1],"methotrexate":[2,156],"(HDMTX)":[3],"and":[4,37,61,119,177,181,223,356,415],"asparaginase":[5],"(ASP)":[6],"play":[7],"crucial":[8],"roles":[9],"in":[10,87,198,298,324,421],"the":[11,32,52,88,100,165,184,201,214,226,252,281,286,373,409,416],"multi-agent":[12],"chemotherapy":[13,56],"used":[14,211],"to":[15,34,78,124,134,212,256,280,305,333,382,391,399,407],"cure":[16],"children":[17],"with":[18,82,113,240,266,268,326,335,370,397],"acute":[19],"lymphoblastic":[20],"leukemia":[21],"(ALL).":[22],"Individualized":[23],"dosing":[24],"of":[25,44,54,71,117,130,143,149,155,186,225,244,246,273,284,375,395,411,419],"HDMTX":[26,45,106,151,171,258,288,318,360,371,376,396],"based":[27],"on":[28,146,359],"its":[29,379],"pharmacokinetics":[30,172,190,374],"has":[31],"potential":[33,417],"improve":[35],"efficacy":[36],"reduce":[38],"toxicity.":[39,402],"While":[40],"a":[41,114,126,269],"few":[42],"predictors":[43],"pharmacokinetics,":[46],"such":[47,58],"as":[48,59],"SLCO1B1,":[49],"are":[50,65],"recognized,":[51],"impact":[53],"concomitant":[55,302],"agents,":[57],"ASP,":[60],"other":[62,423],"genetic":[63],"variations":[64],"not":[66,309],"well-established.":[67],"Methods:":[68],"A":[69,206],"cohort":[70],"302":[72,237],"standard/high-risk":[73],"(SR/HR)":[74],"patients,":[75],"aged":[76],"1":[77],"18":[79],"years":[80],"old,":[81],"newly":[83],"diagnosed":[84],"ALL":[85],"participated":[86],"Total":[89],"XVII":[90],"trial":[91],"at":[92,178],"St.":[93],"Jude":[94],"Children\u2019s":[95],"Research":[96],"Hospital":[97],"(NCT03117751).":[98],"During":[99],"consolidation":[101,166,292],"phase,":[102],"SR/HR":[103,238],"patients":[104,239],"received":[105,139,301],"every":[107],"2":[108,142,312],"weeks":[109],"for":[110,170],"4":[111],"courses":[112],"first":[115],"dose":[116,289],"5g/m2":[118],"subsequent":[120],"doses":[121],"pharmacokinetically":[122],"guided":[123],"target":[125],"steady-state":[127],"plasma":[128],"concentration":[129],"65":[131],"\u03bcM.":[132],"Prior":[133],"December":[135,159],"2019,":[136,160],"they":[137],"also":[138,232],"1000":[140],"units/m":[141],"PEG-asparaginase":[144],"(PEG-ASP)":[145],"day":[147],"3":[148],"each":[150],"cycle":[152],"pending":[153],"clearance":[154,259,272,319,361],"(MTX).":[157],"After":[158],"PEG-ASP":[161,303,357,368,398],"was":[162,210,231,254,260,295,320,349],"removed":[163],"from":[164],"phase.Serial":[167],"blood":[168],"samples":[169],"monitoring":[173],"were":[174,191,218,236,249],"collected":[175],"pre-infusion":[176],"6,":[179],"23,":[180],"42-hours":[182],"after":[183],"start":[185],"infusion.":[187],"MTX":[188],"population":[189],"estimated":[192,217],"using":[193,200],"nonlinear":[194],"mixed-effects":[195],"models":[196],"implemented":[197],"Monolix":[199],"Stochastic":[202],"Approximation":[203],"Expectation-Maximization":[204],"method.":[205],"linear":[207],"two-compartment":[208],"model":[209],"fit":[213],"data.":[215],"Parameters":[216],"clearance,":[219,222],"volume,":[220],"intercompartmental":[221],"volume":[224],"peripheral":[227],"compartment.":[228],"Whole-genome":[229],"sequencing":[230],"available.":[233],"Results:":[234],"There":[235,348],"1088":[241],"evaluable":[242],"cycles":[243,293],"HDMTX,":[245,285],"which":[247],"220":[248],"given":[250,265,290],"when":[251,264],"patient":[253],"exposed":[255],"PEG-ASP.":[257],"14%":[261],"(p=9.1\u00d710\u201312)":[262],"lower":[263,297,323],"PEG-ASP,":[267],"post-hoc":[270],"median":[271,287,341],"76.9":[274],"vs":[275,313,344],"98.2":[276],"mL/min/m":[277,346],"2.":[278],"Due":[279,381],"pharmacokinetic":[282],"targeting":[283],"during":[291],"2-4":[294],"significantly":[296],"those":[299,306,325,334],"who":[300,307],"compared":[304,332],"did":[308],"(3.56":[310],"g/m":[311,315],"4.02":[314],"2;":[316],"p=0.047).":[317],"8.9%":[321],"(p=6.1\u00d710-3)":[322],"SLCO1B1":[327,354],"decreased":[328],"or":[329,337],"poor":[330],"function":[331,339],"normal":[336],"increased":[338],"(post-hoc":[340],"clearance:":[342],"83.3":[343],"94.7":[345],"2).":[347],"no":[350],"significant":[351,385],"interaction":[352,414],"between":[353],"phenotype":[355],"exposure":[358],"(p=0.38).":[362],"Conclusions:":[363],"Our":[364],"results":[365],"indicate":[366],"that":[367],"administered":[369],"alters":[372],"by":[377],"reducing":[378],"clearance.":[380],"this":[383,412],"clinically":[384],"interaction,":[386],"protocols":[387],"should":[388],"be":[389],"designed":[390],"avoid":[392,400],"concurrent":[393],"administration":[394],"excessive":[401],"Further":[403],"investigation":[404],"is":[405],"needed":[406],"determine":[408],"mechanism":[410],"drug":[413],"effects":[418],"variants":[420],"genes":[422],"than":[424],"SLCO1B1.":[425],"Citations:":[426],"N/A":[427]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2025-02-19T00:00:00"}